POSB87 Carbon Footprint Impact of Breezhaler ® Dry Powder Inhaler for Asthma: An Analysis in UK and Italy
Policy interventions to reduce climate impacts are being increasingly considered by healthcare decision-makers in many countries, such as the National Health Service in England and Ministero della transizione ecologica in Italy. Dry powder inhalers (DPIs) for the treatment of asthma demonstrated significantly lower greenhouse gas emissions than pressurised metered-dose inhalers. An analysis was conducted to estimate the reduction in carbon dioxide equivalent (CO2e) emissions related to once-daily indacaterol acetate/mometasone furoate (IND/MF) and once-daily indacaterol acetate/mometasone furoate/glycopyrronium bromide (IND/GLY/MF), delivered using Breezhaler ® DPI device, compared to existing inhalers in the UK and Italy.
Source: Value in Health - Category: International Medicine & Public Health Authors: A Choubey, J Marvel, R Ishikawa, H Kaur, A Tedeschi, D Ritrovato, S Sydnor, P Thokala Source Type: research
More News: Asthma | International Medicine & Public Health | Italy Health | Mometasone | Nasonex | National Health Service (NHS) | UK Health